The effect of peripheral neuropathy on daily life activities in patients receiving chemotherapy (original) (raw)
Related papers
Cancer Nursing, 2011
Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect of several chemotherapy drugs used for the treatment of many common malignancies. CIPN is both under-assessed and underreported and few self-report tools exist that measure CIPN. Existing instruments do not evaluate all of the multi-dimensional characteristics of neuropathic symptoms; intensity, distress, timing, and characteristics. The purpose of this descriptive, cross-sectional study was to develop and psychometrically evaluate a new self-report tool for CIPN, the Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT). Interviews with 15 patients with known CIPN guided development of the CIPNAT. The CIPNAT is a 69 item self-report tool which measures CIPN, including characteristics, intensity, distress, frequency, and interference with usual activities. Content validity was evaluated by a panel of experts and revisions were made to the CIPNAT based on those results. The CIPNAT was administered to 167 patients on chemotherapy at H. Lee Moffitt Cancer Center and a two physician medical oncology practice in Tampa, Florida. The Functional Assessment of Cancer Therapy-Neurotoxicity scale (FACT/GOG-Ntx), another self-report tool for CIPN was also administered. vii Correlations between the CIPNAT and the FACT/GOG-Ntx were evaluated. Differences between a group of 40 patients getting non-neurotoxic chemotherapy and a group of 127 patients getting neurotoxic chemotherapy were also examined. Test-retest reliability was evaluated by administering the CIPNAT a second time to a subgroup of 30 patients and correlating the results. Correlation with a measure of the same concept indicated that scores between the CIPNAT and the FACT-Ntx were strong (r =.73, p=.000, n=127).Differences between the two contrasting groups were significant (p = .000), supporting validity. High test-retest correlations (r =.921, p=.000) demonstrated reliability. Cronbach's alpha for the total CIPNAT (alpha=.945), the symptom experience scale (alpha =.927) and the interference scale (alpha=.897) demonstrated high internal consistency reliability. Confirmatory factor analysis of neuropathic symptoms indicated the presence of two underlying factors, sensory symptoms and motor symptoms. Confirmatory factor analysis of the interference scale also indicated two underlying factors, activities requiring manual dexterity and general activities. These results provide strong evidence of the validity and reliability of the CIPNAT. higher risk as are those with preexisting neuropathy (Badros et al., 2007; Chaudhry,
Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment?
Annals of Oncology, 2013
This assessor-blinded, prospective, randomized controlled clinical trial aimed at investigating the effect of classical massage on chemotherapy induced peripheral neuropathy and the quality of life (QOL) in breast cancer patients receiving adjuvant paclitaxel. Methods: A total of 40 female breast cancer patients were randomly allocated to the classical massage group (CMG) or the control group (CG). Classical massage was applied to the patients in the CMG before each paclitaxel infusion. The CG received only usual care. Presence of peripheral neuropathic pain and QOL were assessed at baseline and weeks 4, 8, 12, and 16. Nerve conduction studies (NCS) findings were also recorded at baseline and week 12. Results: The peripheral neuropathic pain was lower in the CMG compared to the CG at week 12 (p<0.05). The sensory and motor sub-scale scores of the QOL measure showed statistically significant differences over time in favor of the CMG (p<0.05). Sensory action potential amplitude of the median nerve was significantly higher and the tibial nerve latency was significantly shorter in the CMG compared to the CG at week 12. Conclusions: This study suggested that classical massage successfully prevented chemotherapy-induced peripheral neuropathic pain, improved the QOL, and showed beneficial effects on the NCS findings.
Journal of the advanced practitioner in oncology, 2012
The focus of this study was to assess the feasibility and clinical implementation of a standardized assessment for chemotherapy-induced peripheral neuropathy (CIPN) by registered nurses in patients undergoing neurotoxic chemotherapy. A total of 24 registered nurses from 4 different institutions were enrolled into the study. A pre- and posttest design was used to assess changes in nurses' attitudes, knowledge, and perceived skill in CIPN assessment. Using selected data collection instruments, nurses performed standardized assessments during the course of chemotherapy treatments. Patient-reported symptoms, vibratory sensation, deep-tendon reflexes, and touch were collected at three time points during chemotherapy treatment. Results indicated there was no statistically significant change in knowledge of chemotherapy-induced peripheral neuropathy from baseline to the end of the study. However, this finding may be due to poor internal consistency noted among the items of the Nurse Kn...
Rehabilitation oncology, 2010
BACKGROUND AND OBJECTIVES: Chemotherapy-induced peripheral neuropathy is the most common neurological syndrome secondary to antineoplastic therapy primarily affecting patients being treated with taxanes and platinum derivatives. Sensory neuropathy is the most frequent type. This study aimed at carrying out a narrative review of the literature on the pathophysiology, clinical manifestations, impact, evaluation, diagnosis treatment and prevention of chemotherapy-induced peripheral neuropathy. CONTENTS: Recent studies have shown association among inflammatory molecules, oxidative stress and development of chemotherapy-induced peripheral neuropathy. Most frequent symptoms are limbs numbness and tingling, with neuropathic pain having significant impact on the functionality of patients submitted to antineoplastic therapy. Several evaluation tools have been tested, being electroneuromyography considered the golden standard for chemotherapy-induced peripheral neuropathy diagnosis. There are different pharmacological strategies for its therapy and prevention. CONCLUSION: It is known that chemotherapy-induced peripheral neuropathy is a frequent syndrome negatively interfering with cancer patients' treatment and quality of life. Different drugs are associated to different risk levels, which show its neurobiological complexity. Prevention, diagnostic and treatment strategies have to greatly evolve to minimize its frequency and severity.
European Journal of Oncology Nursing, 2017
Chemotherapy-induced peripheral neuropathy is a common treatment-related adverse effect. It adversely affects the quality of life. Therefore, it is important to evaluate symptoms. The purpose of this study was to evaluate the validity and reliability of Chemotherapy-Induced Peripheral Neuropathy Assessment Tool in Turkish patients. Methods: A convenience sample of 327 patients, being treated with peripheral neurotoxic chemotherapeutic agents were asked to fill in the questionnaire. The data was evaluated using SPSS 21 (SPSS Inc., Chicago IL, USA) statistical software. The verification of the structure obtained with CFA was provided by AMOS 21.0. Psychometric testing included internal consistency reliability (Cronbach's alpha coefficient and item-total correlations), test-retest reliability, validity (exploratory factor analysis, confirmatory factor analysis and concurrent validity). Results: The Cronbach alpha value of the scale was 0.97. The test-retest reliability results were significantly high. The CIPNAT significantly correlated with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy. The model was validated by confirmatory factor analysis (χ2/sd = 2.74, GFI = 0.95, AGFI = 0.92, CFI = 0.98, RMSEA = 0.07, and RMR = 0.009). Conclusions: The Turkish version of the CINAT was found to be reliable and valid with Turkish patients receiving chemotherapy. Use of the CIPNAT may lead to a better understanding of symptom. The CIPNAT can be used in future nursing research and practice as an assessment tool for peripheral neuropathy in patients with cancer who undergo chemotherapy.
Physiotherapy management of chemotherapy-induced peripheral neuropathy in Pretoria, South Africa
South African Journal of Physiotherapy
Background: The increase in newly diagnosed patients with cancer in South Africa and globally, may contribute to the increase in patients living with chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy-induced peripheral neuropathy negatively impacts on quality of life (QoL) during and post chemotherapy treatment. Physiotherapy management of CIPN helps patients to manage symptoms and improves function in activityand participation-levels to ultimately improve QoL. However, little evidence exists regarding the type or combination of physiotherapy management strategies in South Africa. Objectives: The purpose of our study was to determine how the symptoms of CIPN were managed by physiotherapists in Pretoria, South Africa. Method: A quantitative, descriptive study design was used. Electronic questionnaires were distributed to physiotherapists who worked with cancer patients and who treated patients with CIPN.
European Journal of Cancer, 2005
Chemotherapy-induced peripheral neuropathy (CIPN) is a common phenomenon, often resulting in serious limitations in daily functioning and comprosised quality of life. Currently available toxicity grading systems typically use a combination of clinical and paraclinical parameters and relies on the judgment of clinicians and/or nurses. However, because many of the symptoms of CIPN are subjective in nature, it is only logical that an assessment of CIPN be based, at least in part, on patient self-report data. We report on the development of a patient self-report questionnaire, the CIPN20, intended to supplement the core quality of life questionnaire of the European Organization for Research and Treatment of Cancer (EORTC). Following EORTC guidelines, relevant CIPNrelated issues were identified from a literature survey and interviews with health professionals (n = 15) and patients (n = 112). The resulting 20-item questionnaire was pre-tested in three languages and four countries and is currently being examined in a large, international clinical trial. The EORTC CIPN20 should provide valuable information on CIPN-related symptoms and functional limitations of patients exposed to potentially neurotoxic chemotherapeutic and/or neuroprotective agents.
2019
Objectives: The aim of this study was to evaluate peripheral n europathy-related quality of life in chemotherapyreceived patients with the diagnosis of hematologic al cancer. Methods: This descriptive study was conducted on the patient s who accepted to participate in the research and received chemotherapy for the first time and at lea st 3 cycles between January and October 2016 in a h ospital in İzmir. The data of the study were collected by using the Individual Identification Form, the National C ancer Institute Common Toxicity Criteria Sensory and Moto r Neuropathy Scale, and the European Organization f or Research and Treatment of Cancer Quality of Life Qu stionnaire Chemotherapy-Induced Peripheral Neuropa thy Scale (EORTC QLQ-CIPN 20). In the study, values bel onging to categorical variables were presented as frequency and percentage. Mann Whitney U test was u sed in comparison of two groups with non-normal distribution. Results: The mean age of 115 patients who participated i...